Soluble TSGL Therapy for Cytokine Release Syndrome in T Cell Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing T cell activating therapies cause cytokine release syndrome (CRS), leading to adverse side effects such as vascular inflammation and neurotoxicity, while agents like tocilizumab may reduce therapeutic anti-cancer activity.
Innovation Solution
Administering soluble forms of PSGL-1, such as TSGL molecules or TSGL fusion proteins, to prevent endothelial damage and reduce CRS, maintaining T cell therapeutic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell activating therapies are administered, then anti-cancer therapeutic activity is improved, but cytokine release syndrome and vascular inflammation occur causing adverse side effects
Solution Approach 1:
The patent uses soluble selectin molecules as intermediary agents that bind to PSGL-1 on T cells and leukocytes, blocking their interaction with endothelial selectins. This mediator prevents the harmful adhesion and vascular inflammation caused by CRS while allowing T cell activation and anti-cancer activity to proceed. The soluble selectin acts as a decoy receptor that intercepts the pathological interaction without compromising therapeutic efficacy.
Solution Approach 2:
The patent extracts and neutralizes the harmful component of the immune response by administering soluble selectin molecules that specifically bind to and remove the adhesion signal from circulation. By taking out the pathological T cell-endothelium adhesion interaction, the therapy prevents vascular damage and neurotoxicity while preserving the desired anti-tumor immune activity.
2Object-affected harmful factors
If agents like tocilizumab are administered to reduce CRS, then adverse side effects are reduced, but therapeutic anti-cancer activity is compromised
Solution Approach 1:
The patent applies local quality by targeting specifically the adhesion pathway involving selectins and PSGL-1, rather than broadly suppressing immune activity like IL-6 receptor blockade. This localized intervention blocks only the harmful vascular adhesion aspect of CRS while leaving other anti-cancer immune mechanisms intact, thus preserving therapeutic activity while reducing adverse effects.
Solution Approach 2:
Instead of using IL-6 receptor antagonists that broadly suppress immune responses, the patent introduces soluble selectin molecules as a more specific intermediary that blocks only the pathological T cell-endothelium adhesion. This selective mediation preserves anti-cancer T cell activity while preventing CRS-related vascular damage.
3Object-affected harmful factors
If soluble PSGL-1 molecules are administered, then endothelial damage is prevented and CRS is reduced, but T cell therapeutic activity may be compromised
Solution Approach 1:
The patent employs partial action by using soluble selectin molecules at concentrations sufficient to block pathological adhesion but not so high as to completely inhibit all T cell-endothelium interactions needed for therapeutic activity. The dosing and molecular design are optimized to achieve partial blockade that prevents CRS while preserving necessary immune function.
Solution Approach 2:
The patent utilizes parameter changes by modifying the structure and concentration of soluble selectin molecules to optimize their binding affinity and specificity. By adjusting these parameters, the therapy achieves a balance where enough adhesion is blocked to prevent CRS, but sufficient T cell activation and trafficking remain to maintain anti-cancer efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Prevents endothelial damage and reduces CRS severity without compromising the anti-cancer efficacy of T cell therapies.
Implementation Method 1
The selectin proteins are characterized by an N-terminal lectin-like domain... All three of the selectins bind, with varying affinity, to a ligand called PSGL (P-selectin glycoprotein ligand)... Interaction of selectins with PSGL, which is expressed on some circulating lymphocytes and leukocytes, causes those circulating cells in the vasculature which express the active form of PSGL to attach to platelets and/or the endothelium
Data Source
AI summary
Methods of using soluble tandem selectin glycoprotein ligand (TSGL) and TSGL fusion proteins, such as TSGL-Ig, for therapeutic treatment of cancers, including in combination with T cell activation therapies or an adoptive cell transfer (ACT) therapy.